1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsArtificial Intelligence for Health and Biomedical Research is sponsored by National Institutes of Health (NIH). This grant supports research projects that apply artificial intelligence to health and biomedical research, including patient companion technologies for chronic disease management.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Bridge to Artificial Intelligence (Bridge2AI) | NIH Common Fund Bridge to Artificial Intelligence (Bridge2AI) Bridge to Artificial Intelligence (Bridge2AI) NIH Common Fund’s Bridge to Artificial Intelligence Program (Bridge2AI) The NIH Common Fund’s Bridge to Artificial Intelligence program (Bridge2AI) aims to bridge the gap between biomedical and behavioral research and artificial intelligence (AI).
Learn how this exciting new program will bring together diverse teams to generate tools, resources, and richly detailed AI-ready data that is accurate, reliable, and ethically sourced. The program will also create training materials, best practices, and activities to support workforce development across different research communities.
The NIH Common Fund’s Bridge to Artificial Intelligence (Bridge2AI) program will propel biomedical research forward by setting the stage for widespread adoption of artificial intelligence (AI) that tackles complex biomedical challenges beyond human intuition.
Resources from Bridge2AI Stage I The first stage of the Bridge2AI program tackled a key gap in the biomedical research community by generating new “flagship” data sets and best practices for machine learning (ML) analysis. These datasets were collected and processed with AI modeling in mind.
To complement these datasets, the program also developed: software, standards, tools, best practices and training materials for workforce development. The resources generated by the first stage of the program are available through the Bridge2AI portal .
The second stage of the program will build upon the accomplishments of Stage 1 to use the generated data, tools and best practices to deliver trusted solutions to address major biomedical and behavioral health challenges.
The second stage of Bridge2AI will support two initiatives to propel AI health research: Innovation Funnels – Using AI-ready datasets (including datasets from Bridge2AI Stage 1), the innovation funnels will create tools, devices, and novel insights that use AI to improve health.
Network for AI Health Science - The program will create a network for AI health science that will bring together a network of scientific experts to develop safety measures for responsible AI use and research. This network will also build a framework to inform future AI health sciences research.
Together, the Innovation Funnels and Research Network will generate an ecosystem of research teams that will use AI-enabled tools and solutions to address key health challenges. By improving health and promoting responsible use of AI in medicine, the program aims to build public trust in AI-informed health research and care.
Bridge2AI Approved for 2nd Stage, watch the Jan 2026 Council of Council presentation (starts at 04:03:00) Bridge2AI investigator, Dr. Yael Bensoussan, shares how voice and AI could help detect disease on the Chasing Life podcast Bridge2AI preliminary datasets now available Dr. Chris Kinsinger, Bridge2AI Program Officer, meets with other health care experts at the Health IT Summit to weigh in on AI Learn about the exciting work our researchers are doing.
Team Building & Networking Visit the Bridge2AI Platform (registration required) to hear from NIH leaders, watch videos from the June 2021 Team Building Activities, and join the conversation on Slack . NIH Institute and Center Directors’ Welcome This page last reviewed on
According to the current listing, eligibility includes: Nonprofit organizations, universities, and research institutions. Confirm the full requirements in the official notice before applying.
Artificial Intelligence for Health and Biomedical Research is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.
NIH R25 Summer Research Education Experience Program is a grant from the National Institutes of Health (NIH) that funds universities and institutions of higher education to provide summer research experiences in environmental health sciences to high school students, college undergraduates, and science teachers. Administered through the National Institute of Environmental Health Sciences (NIEHS), the program aims to attract young people to scientific careers and help teachers communicate about the scientific process more effectively. Eligible applicants are U.S. institutions eligible for NIH grants. The application deadline was March 17, 2026.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
The April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read articleNIH has no active SBIR or STTR omnibus solicitations for the first time in a decade. The FY26 reset reposts the omnibus series on June 1 with a September 8 deadline and a quietly historic change — Direct-to-Phase II STTR awards. Here is the strategy.
Read article